白内障超声乳化吸除术前后黄斑区厚度变化的OCT观察

目的：：观察白内障超声乳化联合人工晶状体植入术对白内障患者黄斑中心凹视网膜厚度变化的影响。方法：将60例白内障患者的手术眼作为手术组,对侧眼作为对照组,两组术前、术中无并发症,术前和术后1 wk;1,3,6 mo黄斑区行OCT测量,观察两组术后黄斑中心凹视网膜厚度变化。结果：手术组：术后1 wk和1,3 mo黄斑中心凹视网膜厚度与术前相比,均有统计学差异(P<0.05),术后6mo黄斑中心凹视网膜厚度与术前相比,无统计学差异(P>0.05),术后1 mo黄斑中心凹视网膜厚度明显高于其他组(P<0.05)。其中12眼术后出现黄斑水肿,均发生于术后2~4wk,包括10眼中心凹增厚及2眼黄斑囊样水肿,其中11眼于6 mo内自愈。对照组：术前黄斑中心凹视网膜厚度与术后1 wk;1,3,6 mo相比,均无统计学差异(P>0.05)。手术组与对照组：两组术前、术后6mo黄斑中心凹视网膜厚度对比,均无统计学差异(P>0.05),两组术后1 wk和1,3 mo黄斑中心凹视网膜厚度对比,均有统计学差异(P<0.05)。结论：白内障超声乳化联合人工晶状体植入术后黄斑中心凹视网膜厚度显著增加,少数患者会出现黄斑水肿,但绝大多数患者可自愈,预后良好。     

手法小切口白内障手术与超声乳化术后糖尿病患者黄斑厚度的对比

目的 比较手法小切口白内障手术与超声乳化手术对Ⅱ型糖尿病患者黄斑中心凹厚度的影响.方法 56例（56只眼）合并Ⅱ型糖尿病患者的白内障随机分成两组,分别施行手法小切口白内障手术及超声乳化吸出手术.所有患者术前均行眼底检查及眼底照像,术前1个月、术后1周、4周、6周、3个月OCT测量黄斑中心凹厚度,并分析此厚度与最佳矫正视力的相关性.结果 26只眼手法小切口白内障手术,30只眼超声乳化吸出手术,两组患者术后黄斑水肿发生率差异无统计学意义.术后1周,手法组黄斑中心凹视网膜神经上皮层厚度明显高于超乳组（t=4.602,P=0.006）,最佳矫正视力明显低于超乳组（χ2=9.753,P=0.009）,4周后两组黄斑中心凹视网膜神经上皮层厚度和最佳矫正视力差异均无统计学意义.最佳矫正视力与黄斑中心凹视网膜神经上皮层厚度呈现负相关.结论 虽然Ⅱ型糖尿病患者的白内障手法小切口白内障手术和超声乳化吸出术后黄斑水肿发生率无差异,但是术后短期内手法小切口手术对黄斑中心凹视网膜神经上皮层厚度影响较大,并暂时影响最佳矫正视力.     

白内障超声乳化手术后黄斑区光学相干断层扫描

目的:观察白内障超声乳化吸除联合人工晶状体植入术后黄斑中心凹厚度的改变。方法:对行白内障超声乳化吸除联合人工晶状体植入术,且术前、术中无并发症患者56例56眼,行术前及术后1,3mo黄斑区OCT检查,观察术眼黄斑中心凹厚度变化及视力变化。结果:56眼黄斑中心凹视网膜平均厚度术前为241.3±9.9μm,术后1mo为(260.7±16.8)μm,术后3mo为(245.6±17.6)μm,术后1mo与术前比较,差异有显著性意义(P=0.000),术后3mo与术前比较,差异无显著性意义(P=0.137)。术后1mo,2眼出现黄斑囊样水肿,术后3mo,1眼黄斑囊样水肿消退,另1眼黄斑囊样水肿较前略降低,其余眼未出现黄斑囊样水肿。结论:白内障超声乳化吸除联合人工晶状体植入术后1mo黄斑中心凹厚度明显增加,术后3mo大部分黄斑水肿消退。     

年龄相关性白内障手术前后黄斑厚度观察

目的应用光学相干断层扫描（OCT）技术检测单纯年龄相关性白内障超声乳化并人工晶状体植入手术前后黄斑区视网膜厚度。方法对行超声乳化吸出术,且术前无合并症、术中无并发症的单纯年龄相关性白内障86例（104只眼）于术前及术后1周、1个月、3个月分别以OCT观察黄斑中心凹及黄斑区视网膜平均厚度的变化情况。结果所有术眼术后最佳矫正视力0．3～1．0,均较术前提高,OCT检查结果显示与术前比较术后1周黄斑中心凹厚度无增加,差异无统计学意义（t=-1．554,P=0．122）,而黄斑区视网膜厚度增加,差异有统计学意义（t=-2．557,P=0．011）;手术后1个月黄斑中心凹厚度和黄斑区视网膜厚度与术前比较均有增加,差异有统计学意义（t=-3．975,P=0．000;t=-2．862,P=0．005）;术后3个月两区域厚度与术前比较差异均无统计学意义（t=-1．568,P=0．118;t=-0．197,P=0．844）。结论黄斑区视网膜平均厚度的检测可能比单纯黄斑中心凹厚度的检测更早、更全面地反映出患者白内障术后视网膜厚度增加的情况,为白内障术后黄斑水肿的诊治提供更多可靠依据。     

白内障超声乳化术后应用活血化淤汤的临床观察

背景白内障超声乳化联合人工晶状体（IOL）植入术后的黄斑水肿是影响视功能的主要原因,中医药疗法减轻组织水肿疗效独特,但其对白内障超声乳化术后黄斑水肿的防治作用少有报道。目的探讨口服活血化淤汤对白内障超声乳化联合IOL植入术后黄斑区的保护作用。方法采用病例对照研究设计。单纯年龄相关性白内障行常规超声乳化联合IOL植入术150例180眼分为单纯手术组和手术＋药物组。单纯手术组86例100眼仅行手术治疗,手术＋药物组64例80眼手术后给予活血化瘀汤12I服14d。两组分别于术前,术后1、2、4、6、8和12周对比患眼的最佳矫正视力、角膜反应及前房反应、黄斑中心凹视网膜厚度及黄斑区组织变化情况。结果术后12周手术＋药物组视力≥1．0的跟数分布基本与单纯手术组持平,差异无统计学意义（χ^2=1．066,P〉0.05）。术后1周手术＋药物组房水闪辉的眼数明显少于单纯手术组,差异有统计学意义（χ^2=9．341,P〈0.05）。单纯手术组、手术＋药物组术后2～8周中心凹厚度与术前比较差异均有统计学意义（P〈0.05）,术后2～8周手术＋药物组中心凹厚度低于单纯手术组,差异均有统计学意义（t=2．315、2．323、3．104、2．470,P〈0.05）。单纯手术组13眼（13／100,占13％）出现术后黄斑水肿,均发生于术后2～6周,包括中心凹增厚11眼,黄斑囊样水肿2眼,其中10眼术后12周内水肿消失。手术＋药物组3眼（3／80,占3．75％）出现术后黄斑水肿,包括黄斑中心凹增厚2眼及黄斑囊样水肿1眼,发生于术后4—6周,术后12周水肿消失。结论活血化淤汤能够促进超声乳化联合IOL植入术后眼前节炎症的恢复,改善术后黄斑区的功能。     

超声乳化晶状体摘除治疗合并特发性黄斑前膜的白内障

目的：探讨合并特发性黄斑前膜的白内障患者行超声乳化晶状体摘除+人工晶状体植入术的临床疗效。 方法：回顾分析2008-01/2011-10于我院行超声乳化晶状体摘除+人工晶状体植入术的合并特发性黄斑前膜的白内障患者112例118眼,根据临床表现和OCT检查结果按早期、增殖期、牵拉期予以分组,分别于术前、术后1wk;6mo检测患者裸眼视力、最佳矫正视力,OCT检测黄斑中心凹视网膜厚度及视网膜组织变化情况并予以比较。 结果：所有患者术后6mo裸眼视力及最佳矫正视力较术前均有不同程度提高。术后最佳矫正视力早期组≥0.5者100%,增殖期组≥0.5者73%,牵拉期组≥0.1者53%。术后6mo,OCT检测黄斑中心凹视网膜厚度较术前变化均无统计学意义,牵拉期组患者有2例最终行玻璃体切除+黄斑前膜剥离术。 结论：超声乳化晶状体摘除+人工晶状体植入术对于合并特发性黄斑前膜的白内障患者可以改善视觉质量,并不会加重原有眼底病变,是一种安全有效的治疗方法。但对于黄斑前膜已处于牵拉期的白内障患者,单纯白内障手术对术后视力改善有限,建议联合或再行眼底手术治疗。     

不同手术方式对高度近视合并白内障患者黄斑区视网膜厚度及视力的影响

目的比较高度近视合并白内障患者进行小切口手法碎核白内障摘出术与白内障超声乳化吸出术对黄斑区视网膜厚度的影响。方法 64例(80眼)高度近视合并白内障患者随机分为A、B两组,A组行小切口手法碎核白内障手术,B组行白内障超声乳化吸出术。术后1周、4周、8周和12周观察两组患者最佳矫正视力(best corrected visual acuity,BCVA),术前及术后1周进行角膜内皮细胞计数。采用Zeiss-Humphrey OCT3仪于术前1周,术后1周、4周、6周、8周和12周分别检查术眼黄斑中心凹视网膜厚度。结果 A、B组术后BCVA较术前均有所提高,差异均有统计学意义(均为P<0.05),术后各时间点两组BCVA比较差异均无统计学意义(均为P>0.05)。A、B两组术后角膜内皮细胞丢失率分别为6.95%和7.19%,差异无统计学意义(P>0.05)。A、B组术后1周时黄斑中心凹视网膜厚度分别为(189.37±24.95)μm和(191.87±22.61)μm,与术前(158.13±19.11)μm和(159.20±16.18)μm相比,差异均有统计学意义(均为P<0.05),组间比较差异无统计学意义(P>0.05);术后4周、6周时两组黄斑中心凹视网膜平均厚度仍较术前明显增厚,差异均有统计学意义(均为P<0.05),但组间比较差异均无统计学意义(均为P>0.05);术后8周、12周时A、B组黄斑中心凹视网膜厚度均恢复至术前水平,组间比较差异均无统计学意义(均为P>0.05)。B组术后发现黄斑囊样水肿1眼,第12周复查时已消退。结论高度近视合并白内障患者行不同方式白内障手术后早期黄斑区视网膜厚度均有增加,但是大多达不到黄斑囊样水肿的诊断标准,在8周左右黄斑区视网膜厚度几乎恢复正常。     

糖尿病患者超声乳化白内障吸出术后 黄斑改变的光学相干断层扫描

目的观察超声乳化白内障吸出术对糖尿病患者黄斑结构的影响。 方法对比分析30例行超声乳化白内障吸出术的糖尿病患者手术 眼与对侧未手术眼以及30例无糖尿病行超声乳化白内障吸出术者手术前及术后1 d、1个月时 黄斑中心凹厚度的光学相干断层扫描(optical coherence tomography, OCT) 测量资料。 结果糖尿病患者白内障超声乳化手术眼手术前黄斑中心凹的平 均厚度为(148．5±27．7)μm,术后平均厚度为(219．4±68．23) μm,二者比较差异有显著性意义(P<0．05);未手术眼初次检查黄斑中心凹平均厚度为(147．4±27．5) μm,1个月后复查为(148．2±27．3) μm,二者比较差异无显著性意义(P>0．05)。无糖尿病行白内障超声乳化手术眼术前黄斑中心凹平均厚度为(142．37±12．7) μm,术后为(151．9±23．7) μm,二者比较差异无显著性意义(P>0．05)。糖尿病患者白内障超声乳化手术组术后新增黄斑水肿11只眼,原有黄斑水肿的6只眼中3只眼水肿较术前加重。结论 糖尿病患者白内障超声乳化吸出术后视网膜厚度明显增加,黄斑水肿的发生率较高,黄斑水肿的程度较重。(中华眼底病杂志,2001,17:175-177)     

光学相干断层成像术观察超声乳化白内障吸除术后黄斑变化

目的　探讨超声乳化白内障吸除术后黄斑形态的变化及其可能的影响因素。方法　对行超声乳化白内障吸除术 ,且术前无合并症、术中无并发症发生的单纯老年性白内障患者 80例 (80只眼 )于术前和术后 1周分别行光学相干断层成像术 (opticalcoherencetomography ,OCT)检查 ;按术中使用的超声能量高低分成 2个组。观察黄斑中心凹视网膜厚度的变化及其与术中超声能量、术后前房炎性反应和视力的关系。结果　 80只眼黄斑中心凹视网膜平均厚度术前为 (14 2 9± 16 7) μm ,术后为 (15 7 9± 36 7) μm ,两者比较差异无显著意义 (P >0 0 5 )。术后 3只眼出现黄斑水肿 ,11只眼出现房水中度闪光 ,黄斑中心凹视网膜平均厚度术前为 (139 9± 11 3) μm ,术后为 (197 6± 36 9) μm ,两者比较差异有显著意义 (t =2 75 1,P <0 0 5 )。低能量组术后黄斑中心凹视网膜平均厚度为 (15 6 2± 18 3) μm ,高能量组为 (172 6± 32 9) μm ,两者比较差异有显著意义 (t=2 4 11,P <0 0 5 )。术后最佳矫正视力与黄斑中心凹视网膜厚度呈负相关性 (r=- 0 82 ,P <0 0 5 )。结论　超声乳化白内障吸除术可导致术眼黄斑中心凹视网膜厚度增加及黄斑水肿 ;术中高超声能量可明显影响术后黄斑中心凹视网膜的形态 ;术后黄斑中心     

光学相干断层成像术对扭动式超声乳化白内障术后黄斑中心凹视网膜厚度影响的初步研究

目的探讨扭动式超声乳化方式对自内障术后黄斑中心凹视网膜厚度影响。方法分别采用常规式超声和扭动式超声进行晶状体超声乳化手术,对于术中无并发症发生的单纯性老年性白内障60例（64眼）,于术后1周和6周行光学相干断层成像术（OCT）检查,观察不同的超声乳化方式对眼前段及黄斑中心凹视网膜厚度变化的影响。结果常规超声乳化白内障手术组（30眼）黄斑中心凹视网膜厚度（FT）术后1周为（195．6±11．2）μm,扭动组（34眼）为（163．5±10．8）μm（P〈0．05）。术后6周常规组为（223．2±12．8）μm,扭动组为（218．6±14．2）μm（P〉0．05）。术后两组的最佳矫正视力均与黄斑中心凹的视网膜厚度呈负相关（r=-0．75,P〈0．05）。结论常规式超声和扭动式超声均可引起超声乳化吸出术后黄斑区视网膜厚度增加,术后1周内扭动式超声对视网膜厚度的影响较小,优于常规超声。     

年龄相关黄斑变性白内障患者超声乳化人工晶状体植入术后疗效分析

目的:探讨白内障手术对伴有年龄相关黄斑变性(agerelated macular degeneration,AMD)的白内障患者的治疗效果,评价手术的价值。方法:对31例37眼同时伴有AMD的白内障患者行超声乳化人工晶状体植入术,术后随访3～6mo,分析其临床效果。结果:术后所有患者的视力均有不同程度的提高,其中指数2眼(5%),0.01～0.08者11眼(30%),0.1～0.2者12眼(32%),0.3者8眼(22%),0.4～0.5者4眼(11%);术后有1眼(3%)AMD病变加重,为湿性AMD。结论:对于同时伴有AMD的白内障患者,综合考虑其黄斑和晶状体情况,在白内障严重影响视力的情况下,为了提高患者的生活质量,应该积极地进行白内障手术。     

老年黄斑变性合并白内障患者行超声乳化术疗效分析

目的 探讨老年黄斑变性合并白内障患者行超声乳化手术联合人工晶状体植入的临床效果及安全性、可行性.方法 对40例52只眼老年黄斑变性合并白内障患者,行超声乳化联合人丁晶状体植入术,其中干性老年黄斑变性者45只眼,湿性老年黄斑变性者7只眼.收集其资料进行回顾性分析,观察患者术后视力改善情况及有无并发症发生.结果 术后3月时,90.38%患者视力不同程度提高,视力无明显提高甚至下降者5只眼,均为湿性黄斑变性患者.最佳矫正视力0.3-0.6者12只眼(其中达0.6者8只眼),0.1-0.3者35只眼,<0.1者5只眼.4例术中后囊破裂,3例术后角膜雾状水肿.术后1年,7只眼湿性黄斑变性均有不同程度的加重,干性黄斑变性患者未发现眼底新生血管之类改变.结论 超声乳化联合人工晶状体植入术可明显提高老年黄斑变性合并白内障患者术后视力,但对于湿性黄斑变性患者手术应慎重.     

OCT对白内障患者超声乳化术后低视力原因的分析

目的应用相干光断层扫描（OCT）检查的图像特征对白内障患者超声乳化吸除术后低视力的原因进行分析。方法对术后第1~3天矫正视力低于0.3的68例（68只眼）超声乳化术后白内障患者进行OCT检查,分析其图像特征。结果在68例患者中,年龄相关性黄斑病变19例,其中干性11例,湿性8例;糖尿病性视网膜病变15例;高度近视眼底病变14例;黄斑视网膜前膜10例;视网膜静脉阻塞4例;黄斑裂孔3例;视网膜脱离1例;正常眼底2例。结论 OCT作为一种新型的高分辨率的视网膜成像技术,对白内障患者术后低视力的原因的诊断具有重要的作用。年龄相关性黄斑病变、糖尿病性视网膜病变、高度近视眼底病变可能是白内障患者术后低视力的比较常见的原因。     

白内障手术能加快老年性黄斑变性进展吗？

老年人往往同时罹患老年性白内障和老年性黄斑变性两种眼病,长期以来对于白内障手术是否影响老年性黄斑变性的病情一直存在争议。先前的报道多认为白内障手术加快了老年性黄斑变性的进展,而近年的报道多认为白内障手术并未加快老年性黄斑变性的进展,反而更多地改善了患者的视觉功能,这与白内障手术的进步和超声乳化技术的运用是分不开的。（跟科,2010,19：73－75）     

Phacoemulsification does not induce neovascular age-related macular degeneration

PURPOSE: To investigate whether cataract surgery by phacoemulsification induces progression of early age-related macular degeneration (AMD) to neovascular AMD. METHODS: Retrospective case-control study. Included were consecutive patients who had undergone phacoemulsification from January 2000 to February 2006 at the Recklinghausen Eye Centre, who had a preexisting diagnosis of early AMD and who were followed up for at least 1 year after surgery (n = 1152 eyes of 696 patients). The control group comprised phakic patients diagnosed with early AMD from January 2000 to February 2006, who did not undergo eye surgery and were followed up for at least 1 year (n = 334 eyes of 202 patients). RESULTS: At baseline, control eyes had significantly better visual acuity than those of patients who were going to have cataract surgery (0.30/0.35 +/- 0.34 vs. 0.40/0.49 +/- 0.34, respectively; median/mean +/- SD; P < 0.001, Mann-Whitney rank sum test). After 1 year, visual acuity in the control group was worse than in surgical eyes (0.30/0.39 +/- 0.38 vs. 0.20/0.26 +/- 0.30, respectively; median/mean +/- SD; P < 0.001, Mann-Whitney rank sum test). In the cataract surgery group, neovascular AMD developed in 28 (2.43%) of 1152 eyes in the first postoperative year. In the control group, it developed in 6 (1.74%) of 344 eyes within 1 year. There was no significant difference between the groups in the incidence of neovascular AMD (P = 0.57, odds ratio 1.30, 95% CI 0.52-3.24, logistic regression analysis, adjusted for age and baseline visual acuity). CONCLUSIONS: The results indicate that cataract surgery in eyes with early AMD is not a causative factor in neovascular AMD.     

Intravitreal bevacizumab combined with cataract surgery for treatment of exudative macular degeneration.

PURPOSE: The aim of this study was to report on the combination of an intravitreal injection of bevacizumab and cataract surgery in patients with exudative age-related macular degeneration (AMD). METHODS: The interventional case series study included 11 patients (11 eyes) who received an intravitreal injection of 1.5 mg bevacizumab as treatment of exudative AMD (n = 10) or exudative myopic macular degeneration (n = 1), combined with a routine phacoemulsification and posterior chamber lens implantation for treatment of cataract. RESULTS: Intraoperatively and during the follow-up of 150 +/- 77.5 days, there were no complications related to the intravitreal application of bevacizumab combined with cataract surgery, such as wound dehiscence and leakage, delayed wound healing, corneal edema, dislocation of the pseudophakos, rupture of the posterior lens capsule, or rhegmatogenous retinal detachment. CONCLUSIONS: The results of this pilot study suggest that from a safety point of view, intravitreal injections of bevacizumab may be combined with routine cataract surgery.     

玻璃体腔内注射Bevacizumab联合白内障手术治疗湿性年龄相关性黄斑变性(英文)

目的:探讨玻璃体腔内注射bevacizumab (Avastin)联合白内障手术预防脉络膜新生血管(choroidal neovascularization,CNV)的再次激活及年龄相关性黄斑变性(age-relatedmacular degeneration, AMD)。方法:对12例接受湿性年龄相关变性治疗的白内障患者给予透明角膜切口白内障超声乳化和人工晶状体植入手术,最后予以玻璃体腔内注射1.25mg bevacizumab (0.05mL)。主要评价指标:视力恢复、脉络膜新生血管的再次激活,及相干光断层成相术(OCT)对渗漏液体的评估。结果:患者最佳矫正视力(best-corrected visual acuity, BCVA)术后显著提高(脉络膜新生血管闭合后P<0.01,白内障发生后P=0.049,t检验)。白内障术后平均随访时间为11.8mo(标准差6.1,范围3 ～22mo),随访期内患者未出现脉络膜新生血管的再次激活及新的脉络膜新生血管病变。结论:在给予脉络膜新生血管及年龄相关性黄斑变性治疗的患者,白内障手术联合玻璃体腔内注射bevacizumab可预防脉络膜新生血管的再次激活。     

Infrared spectroscopic examination of aqueous humor.

OBJECTIVE: The aim of this study was to report on a new technique for examining aqueous humor. PARTICIPANTS: Aqueous humor samples obtained from 198 patients (cataract: n=66 eyes; age-related macular degeneration [AMD]: n=66; diabetic macular edema: n=66) were in vitro examined by mid infrared spectroscopy. After training and validating the technique, 66 samples were taken for the final independent prediction. RESULTS: In computerized analysis of the spectrometric data, 22 (100%) cataract eyes were diagnosed as the cataract group, 17 (77%) diabetic macular edema eyes were diagnosed as the diabetic macular edema group, and 14 (64%) eyes with AMD were diagnosed as the AMD group. Mid infrared spectrometry could statistically significantly (P=0.004) differentiate between the 3 study groups. CONCLUSIONS: Mid infrared spectroscopic examination of aqueous humor may be able to differentiate eyes with cataract, AMD, or diabetic macular edema.     

The Eger Macular Stressometer: pilot study

PURPOSE: To evaluate the sensitivity of the Eger Macular Stressometer (EMS) for early screening of age-related macular degeneration (AMD) in a clinical practice. We examined the null hypothesis that AMD eyes have EMS recovery times (RTs) that do not differ from eyes with cataract, diabetic retinopathy, or glaucoma. DESIGN: The design of this study was a nonrandomized clinical trial. METHODS: Ninety-two eyes from 92 patients with vision 20/80 or better, age 50 and older, of either gender, and any ethnic origin, were recruited into one of four groups: AMD (30 eyes), normal or mild cataract (30 eyes), diabetic retinopathy (16 eyes), and glaucoma (16 eyes). Recovery times were obtained with the EMS, according to manufacturer's instructions. RESULTS: The mean (SD) [median] RT for the AMD group was 11.8 (7.6) [9] seconds, the normal/cataract group 10.0 (4.3) [9] seconds, the diabetic retinopathy group 8.4 (3.0) [8] seconds, and glaucoma group 8.6 (2.4) [8] seconds. Recovery time did not appear to be related to group (P =.58), age (P =.50), visual acuity (P =.52), or sex (P =.23). CONCLUSIONS: We found EMS RT distributions did not differ between AMD, cataract, diabetic retinopathy, and glaucoma groups. The EMS in its current form is not a sensitive screening tool for AMD. Further testing is needed to examine EMS sensitivity with other macular diseases such as central serous choroidopathy and diabetic macular edema.     

Combined phacoemulsification and pars plana vitrectomy for macular hole treatment

PURPOSE: To assess the outcome of simultaneous phacoemulsification, pars plana vitrectomy and intraocular lens (IOL) implantation in eyes with macular hole. METHODS: A retrospective study was conducted in 38 eyes (36 patients) after combined phacoemulsification, insertion of a posterior capsule IOL and pars plana vitrectomy. RESULTS: The macular hole was successfully closed in 32 of the 38 eyes (84%). In six eyes (16%) the hole failed to close and one eye underwent a second operation. Vision improved by two or more Snellen lines in 29 eyes (73%), there was no change in seven eyes (18%), and visual acuity decreased in two eyes (5%). Intraoperative and postoperative complications included retinal tears in nine eyes (24%), posterior capsule rupture in two eyes (5%), transient postoperative increase of intraocular pressure in eight eyes (21%), and posterior capsule opacification in five eyes (13%). CONCLUSION: Combining phacoemulsification, IOL insertion and pars plana vitrectomy for macular hole repair can reduce the need for cataract surgery in the future, decrease costs, shorten postoperative recovery time and allow for clearer intraoperative visualization, making the procedure safer and more effective.